Welcome to the PACIFICA Trial Information Portal

This is an educational resource for health care professionals to learn more about the ongoing trial and to determine the eligibility for patient enrollment in the trial.

Research Overview

The PACIFICA trial is a randomized, controlled phase 3 study of pacritinib versus Physician's Choice1 in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post‑essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet count <50,000/µL).

1Physician's choice is limited to single drugs (as applicable per country) from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib.

Shape
Image
PACIFICA Trial Objectives

Primary Objectives:

  • To compare the efficacy of pacritinib with that of physician’s choice (P/C) therapy, as assessed by the proportion of patients achieving a ≥35% spleen volume reduction (SVR) from baseline at Week 24 as measured by magnetic resonance imaging (MRI; preferred) or computed tomography (CT) scans
  • To compare the efficacy of pacritinib with P/C therapy, as assessed by the proportion of patients achieving a ≥50% reduction in Total Symptom Score (TSS) from baseline at Week 24

Secondary Objectives:

  • To compare the percentage of patients who self-assess as “very much improved” or “much improved” as measured by the Patient Global Impression of Change (PGIC) in patients treated with pacritinib versus those treated with P/C
  • To compare the overall survival (OS) of patients treated with pacritinib versus those treated with P/C
  • To compare the safety of pacritinib versus P/C therapy
Study Design & Eligibility Criteria

PACIFICA Trial Site Locations

Enrollment is ongoing / proposed in the countries below. For a full list of PACIFICA clinical sites and site enrollment status, visit ClinicalTrials.gov.

World Map
  • United States*
  • Australia
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Georgia
  • India
  • Israel
  • Italy
  • Japan
  • Kazakhstan
  • Korea, Republic of
  • Poland
  • Romania
  • Russian Federation**
  • Serbia
  • Spain
  • Ukraine**
    • >
  • United Kingdom

*Pacritinib (commercially known as VONJO™) was approved by U.S. Food and Drug Administration (FDA) on February 28, 2022 for the treatment of adults with myelofibrosis with a platelet count below 50 x 109/L.

As the approved indication is identical to the patients enrolling on PACIFICA, enrollment of additional patients in the U.S. was closed effective March 2022.

**Enrollment is closed in Russian Federation and Ukraine.




Contact Us
cti biopharma

You are now leaving this page

OK Cancel